Skip to main content

Featured

5 Things to Know Today: July 2, 2026 — CUSMA Non-Renewal, First CGEB Payment & More

  Your quick morning rundown on the money news that matters to Canadians. 1. The U.S. won't renew CUSMA "in its current form" Washington confirmed on July 1 that it will not agree to extend the Canada-U.S.-Mexico Agreement (CUSMA) as written, after the three countries held their first mandatory joint review of the deal. U.S. Trade Representative Jamieson Greer said the agreement "is not renewed" for now, though it stays in force until 2036 and will instead move to a rolling annual review process. Canada's Dominic LeBlanc says Ottawa still wants CUSMA renewed and extended, with talks continuing on outstanding sectoral tariffs affecting steel, aluminum, autos, and lumber. For now, day-to-day trade rules haven't changed, but the uncertainty is expected to weigh on business investment and could resurface as a headwind for the loonie in the months ahead. 2. First Canada Groceries and Essentials Benefit payment lands tomorrow If you're eligible, keep an ey...
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment